700 completed, 79 terminated, 54 recruiting, 42 unknown. 947 Phase 1, 202 Phase 2.
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of HXN-1013 in Healthy Participants and Participants With Mild-to-Moderate Asthma HXN-1013, Placebo - Health Adults, Asthma | Phase 1 | Not yet recruiting | Helixon Biotechnology (Suzhou) Co., Ltd | 40 | 2026-12-01 | 2026-10-28 |
| Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis baricitinib - Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2026-11-02 | 2026-10-28 |
| Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA) Anakinra 100 Mg/0.67 Ml Inj Syringe, Saline Placebo/0.67 Ml Inj Syringe - Asthma (Diagnosis), Persistent Asthma | Phase 1 | Not yet recruiting | University of North Carolina, Chapel Hill | 60 | 2026-11-01 | 2026-07-15 |
| Evaluation of Safety, Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed, Modified and Removed From the Body in Healthy Adults and Adults With Asthma CHF10136, CHF10136 matched placebo - Asthma, Healthy Volunteers | Phase 1 | Recruiting | Chiesi Farmaceutici S.p.A. | 120 | 2026-10-02 | 2026-10-13 |
| Subconjunctival Humira for Boston Keratoprosthesis Adalimumab Injection - Penetrating Keratoplasty, Multiple Graft Failure | Phase 1 | Not yet recruiting | Massachusetts Eye and Ear Infirmary | 8 | 2026-10-01 | 2026-08-31 |
| A Randomized, Double-Blind, Placebo-Controlled Phase Ib Study of Multiple Ascending Doses of EB070 Injection in Adults With Moderate-to-Severe Asthma EB070 - Asthma | Phase 1 | Not yet recruiting | Biotech Pharmaceutical Co., Ltd. | 20 | 2026-09-30 | 2026-10-21 |
| Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis QX4533, QX4533 Placebo - Atopic Dermatitis | Phase 1 | Recruiting | QuantX Biosciences, Inc. | 84 | 2026-09-14 | 2026-10-02 |
| Efficacy and Safety of Yiqi Wenyang Sanhan Formula Combined With Acupoint Application in Patients With Combined Allergic Rhinitis and Asthma Syndrome During Remission and Yang-Deficiency Syndrome Yiqi Wenyang Sanhan Formula Combined with Acupoint Application, placebo of Yiqi Wenyang Sanhan Formula combined with acupoint application - Allergic Rhinitis With Asthma | Phase 1 | Not yet recruiting | Beijing Daxing District Hospital of Integrated Chinese and Western Medicine | 188 | 2026-09-01 | 2026-04-20 |
| Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis HXN6005, Placebo - Health Adult Subjects, Atopic Dermatitis (AD) | Phase 1 / Phase 2 | Not yet recruiting | Helixon Biotechnology (Suzhou) Co., Ltd | 67 | 2026-09-01 | 2026-08-24 |
| A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma SKB575, Placebo - Asthma (Diagnosis) | Phase 1 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 36 | 2026-08-25 | 2026-09-10 |
| A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis BYN-001, Placebo - Atopic Dermatitis, Healthy Participants | Phase 1 | Recruiting | Bionyra Pharma | 56 | 2026-08-17 | 2026-09-30 |
| A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines TLL-018, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 1 / Phase 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 36 | 2026-08-15 | 2026-08-24 |
| A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers AMG 691 - Healthy Participants | Phase 1 | Recruiting | Amgen | 28 | 2026-08-07 | 2026-10-28 |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
| A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283 GSK5784283 - Asthma | Phase 1 | Recruiting | GlaxoSmithKline | 24 | 2026-07-17 | 2026-07-29 |
| A Clinical Study of HRS-8797 in Healthy Participants HRS-8797, Placebo - Atopic Dermatitis | Phase 1 | Not yet recruiting | Chengdu Suncadia Medicine Co., Ltd. | 74 | 2026-07-01 | 2026-07-13 |
| Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2). Alpha-0261, Placebo - Chronic Spontaneous Urticaria (CSU), Healthy Volunteers | Phase 1 | Not yet recruiting | AlphaMol Science Ltd. (Shanghai) | 48 | 2026-07-01 | 2026-07-06 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU) BBT001, Placebo - Chronic Spontaneous Urticaria | Phase 1 / Phase 2 | Recruiting | Bambusa Therapeutics | 48 | 2026-06-29 | 2026-07-22 |
| Safety of MOON101 for the Treatment of Peanut Allergy Dose A, Dose B, Dose C - Peanut Allergy | Phase 1 | Suspended | Moonlight Therapeutics, Inc. | 40 | 2026-06-29 | 2026-10-16 |
| Single Ascending and Multiple Ascending Dose Study of LCA-0061 LCA-0061, Placebo - Atopic Disease, Peanut Allergies | Phase 1 | Recruiting | Lycia Therapeutics, Inc. | 72 | 2026-06-26 | 2026-07-14 |
Showing 20 of 947. Sign in to see all of them.
Asthma (399) · Dermatitis, Atopic (224) · Rhinitis, Allergic (79) · Pulmonary Disease, Chronic Obstructive (46) · Peanut Hypersensitivity (42) · Rhinitis, Allergic, Seasonal (35) · Food Hypersensitivity (34) · Eczema (29) · Chronic Urticaria (23) · Angioedemas, Hereditary (22) · Hypersensitivity, Immediate (20) · Urticaria (20) · Anaphylaxis (15) · Eosinophilic Esophagitis (15)
Immune System Diseases (936) · Hypersensitivity, Immediate (855) · Respiratory Tract Diseases (506) · Respiratory Hypersensitivity (498) · Lung Diseases (404) · Bronchial Diseases (401) · Lung Diseases, Obstructive (400) · Skin and Connective Tissue Diseases (310) · Skin Diseases (300) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (261) · Genetic Diseases, Inborn (259) · Skin Diseases, Eczematous (230) · Skin Diseases, Genetic (230) · Dermatitis (229)
Budesonide (26) · Fluticasone (22) · montelukast (13) · Omalizumab (12) · Sodium Chloride (12) · Charcoal (11) · Saline Solution (11) · Epinephrine (10) · Formoterol Fumarate (10) · Albuterol (8) · Interleukin 1 Receptor Antagonist Protein (8) · Salmeterol Xinafoate (8) · Prednisone (7) · dupilumab (7) · Allergens (6)
GlaxoSmithKline (79) · AstraZeneca (39) · Pfizer (25) · National Institute of Allergy and Infectious Diseases (NIAID) (21) · University of North Carolina, Chapel Hill (18) · Merck Sharp & Dohme LLC (16) · LEO Pharma (14) · Orion Corporation, Orion Pharma (13) · Amgen (11) · Novartis Pharmaceuticals (11) · Chiesi Farmaceutici S.p.A. (10) · Regeneron Pharmaceuticals (10) · MedImmune LLC (9) · Allergy Therapeutics (8) · Boehringer Ingelheim (7)
United States (358) · United Kingdom (125) · Germany (89) · China (87) · Australia (65) · Canada (61) · New Zealand (23) · South Korea (22) · Netherlands (19) · Spain (19) · Belgium (17) · Japan (16) · Finland (13) · Taiwan (11) · Poland (10)
Robert Wood, MD (10) · Michelle Hernandez, MD (5) · Wesley Burks, MD (5) · Edwin Kim, MD (4)
PMID 24184147, PMID 19001265, PMID 22464647, PMID 19680119, PMID 22726593, PMID 23374268, PMID 24035151, PMID 26706294, PMID 29136286, PMID 29550052, PMID 32414772, PMID 32907575, PMID 33463542, PMID 36184023, PMID 38010254, PMID 40185989, PMID 41422501, PMID 10831441, PMID 11069570, PMID 11163535, PMID 11297958, PMID 11468003, PMID 11728816, PMID 12384926, PMID 15201414, PMID 15334472, PMID 15379842, PMID 1538192, PMID 15577929, PMID 15764724, PMID 16164444, PMID 16375711, PMID 16553814, PMID 16899778, PMID 17083353, PMID 17346444, PMID 17717202, PMID 18244953, PMID 18645136, PMID 18951617, PMID 19226304, PMID 19446146, PMID 19647862, PMID 19717725, PMID 19821718, PMID 19944580, PMID 20216101, PMID 20706632, PMID 20921983, PMID 20976161
2014 (11), 2018 (10), 2016 (8), 2015 (7), 2019 (6), 2023 (6), 2009 (5), 2017 (3), 2025 (3), R01HL135235 (3), U19AI095261 (3), P01AT002620 (2), P01AT002647 (2), P01HL158507 (2), 2008 (1)